Buck researchers discover how cellular senescence leads to neurodegeneration

January 29, 2020

Although a link has been established between chronic inflammation and neurodegenerative diseases, there have been many open questions regarding how cellular senescence, a process whereby cells that stop dividing under stress spew out a mix of inflammatory proteins, affects these pathologies. Publishing in PLOS ONE, researchers at the Buck Institute report that senescence in astrocytes, the most abundant cell type in the brain, leads to damaging "excitotoxicity" in cortical neurons that are involved in memory.

This research, led by research scientist Chandani Limbad, PhD, found that cellular senescence in astrocytes downregulates the glutamate transporters, which are vital for glutamate homeostasis in the brain. Glutamate is one of the most important neurotransmitters in the brain; an excess of it causes neurons to repeatedly fire leading to their eventual death. Memantine, an FDA-approved drug for Alzheimer's disease, reduces glutamate toxicity in patients suffering from moderate to severe disease for up to a year, but evidence that the drug might slow pathology is weak. "This study gets to the underlying mechanisms that drive the toxicity," said senior author and Buck professor Judith Campisi, PhD. "We have identified targets that may be of more use in drug development."

Cellular senescence is one of the hottest topics in research on aging. Success in the Campisi lab and others around the world has given rise to companies and research projects aimed at developing either senolytics, drugs that clear senescent cells, or senomorphics, drugs that suppress the senescence-associated inflammation. Earlier work in the Campisi lab in collaboration with the Buck Institute's Andersen lab showed that clearing senescent cells prevented Parkinson's in a mouse model of the disease.

Campisi says that most of the research aimed at understanding the characteristics of cellular senescence involves human fibroblasts, cells in connective tissue which produce collagen and other fibers. She says this work in astrocytes should be a wake-up call to those studying Alzheimer's disease, arguing that, "What is commonly termed non-familial Alzheimer's disease should probably more accurately be termed age-related dementia. If you see five spontaneous Alzheimer's patients, all of them present differently. Some have personality changes, others don't. Memory is affected differently in each patient; some people lose motor control, others don't. These findings highlight aging as the biggest risk factor for almost all neurodegeneration and that is where the research should be focused."

Co-author Pierre-Yves Desprez, PhD, a scientific consultant in the Campisi lab, who also runs a lab at the California Pacific Medical Center Research Institute, says the research also has implications for those studying glioblastoma, a particularly aggressive form of brain cancer which happens in astrocytes. "Cellular senescence is a double-edged sword and the current state of senescence-associated research is messy. While senescence leads to chronic inflammation which promotes cancer and neurodegeneration, it also acts as a tumor suppressor. There are many factors secreted by senescent astrocytes, we think some of them could be exploited as a way to treat glioblastoma."

The research, which involved unbiased RNA sequencing of transcripts expressed by senescent and non-senescent astrocytes, found changes in the expression of more than 5,000 genes whose functions are important in cancer, infectious diseases, and neurological diseases. Results are available to the research community.
-end-
Citation: Astrocyte senescence promotes glutamate toxicity in cortical neurons

DOI: 10.1371/journal.pone.0227887

Other Buck Institute researchers involved in the study include Tal Ronnen Oron, Fatouma Alimirah, Albert R. Davalos, and Tara E. Tracy. Li Gan, from the Gladstone Institute of Neurological Disease was also a contributor.

This work was supported by National Institutes of Health grants AG009909 and AG017242.

Judith Campisi is a scientific co-founder and shareholder of Unity Biotechnology Inc., which has licencing rights to certain patents filed by the Buck Institute.

Buck Institute for Research on Aging

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.